| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.04 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.04 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.41 | 0.04 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.077 | 0.04 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.04 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.12 | 0.04 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.059 | 0.05 |